Oct 1 |
Biohaven prices $250M share offering
|
Oct 1 |
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares
|
Oct 1 |
Acuity Brands, Nike And 3 Stocks To Watch Heading Into Tuesday
|
Sep 30 |
Biohaven proposed public offering of common shares
|
Sep 30 |
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
|
Sep 26 |
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
|
Sep 24 |
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
|
Sep 23 |
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
|
Sep 23 |
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
|
Sep 23 |
Biohaven up 15% on troriluzole trial results for spinocerebellar ataxia
|